Log in

goodpods headphones icon

To access all our features

Open the Goodpods app
Close icon
Experts InSight - Botulinum Toxin in Strabismus

Botulinum Toxin in Strabismus

01/10/25 • 48 min

Experts InSight

Pediatric ophthalmologists Drs. Michelle Cabrera and Alejandra de Alba join host Dr. Ben Young to discuss the pros and cons of using botulinum toxin (Botox) for treating patients with strabismus, and whether every pediatric ophthalmologist—or even general ophthalmologist—should have this technique in their toolbox.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

plus icon
bookmark

Pediatric ophthalmologists Drs. Michelle Cabrera and Alejandra de Alba join host Dr. Ben Young to discuss the pros and cons of using botulinum toxin (Botox) for treating patients with strabismus, and whether every pediatric ophthalmologist—or even general ophthalmologist—should have this technique in their toolbox.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Previous Episode

undefined - Making Sense of Medicare Advantage Plans

Making Sense of Medicare Advantage Plans

Medicare Advantage (MA) plans (also known as "Part C") are rapidly increasing in use, and beneficiaries' co-pay and claims denials are becoming more frequent. In today's episode, host Dr. Andrew Pouw talks with Academy billing and advocacy experts Joy Woodke and Brandy Keys to learn more about MA plans and their impact on patients and how ophthalmologists deliver care.

To review the requirements put forth by your Medicare Administrative Contractor, visit the Academy's page on local coverage determination policies.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Next Episode

undefined - 2025 Retina Update, Part 1: Injectables in the Medical Retina Space

2025 Retina Update, Part 1: Injectables in the Medical Retina Space

Drs. Ashkan Abbey and Ehsan Rahimy join host Dr. Jay Sridhar to discuss recent developments in the medical retina and injectable space, including faricimab versus high-dose aflibercept, biosimilars for ranibizumab and aflibercept, off-label bevacaziumb shortages, dry age-related macular degeneration (AMD) therapies, private equity acquisitions, and the new drug pipeline.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Episode Comments

Generate a badge

Get a badge for your website that links back to this episode

Select type & size
Open dropdown icon
share badge image

<a href="https://goodpods.com/podcasts/experts-insight-622136/botulinum-toxin-in-strabismus-82196018"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to botulinum toxin in strabismus on goodpods" style="width: 225px" /> </a>

Copy